Showing results (101-110 of 731) with videos related to
Sort By:
Pageof 74
Molecular & Cellular Oncology|June 17, 2016
Analysis of intratumor heterogeneity unravels lung cancer evolutionElza C de Bruin, Nicholas McGranahan, Charles SwantonNature Reviews. Clinical Oncology|April 22, 2015
Clinical management of breast cancer heterogeneityDimitrios Zardavas, Alexandre Irrthum, Charles Swanton, et al.Cardio-Oncology (London, England)|November 24, 2022
The spectrum of cardiovascular complications related to immune-checkpoint inhibitor treatment : Including myocarditis and the new entity of non inflammatory left ventricular dysfunctionMaria Sol Andres, Sivatharshini Ramalingam, Stuart D Rosen, et al.Cancer Imaging : the Official Publication of the International Cancer Imaging Society|August 14, 2023
Interpretability of radiomics models is improved when using feature group selection strategies for predicting molecular and clinical targets in clear-cell renal cell carcinoma: insights from the TRACERx Renal studyMatthew R Orton, Evan Hann, Simon J Doran, et al.Arxiv|December 8, 2025
Immunometabolic Gatekeeping: Reconciling Peto's & the T-cell Infiltration Prognostic ParadoxNaomi Iris van den Berg, Matouš Elphick, Kevin Mulder, et al.Cancer Cell|March 27, 2026
Immunometabolic gatekeeping: How tissue metabolism conditions tumor immunityNaomi Iris van den Berg, Matouš Elphick, Kevin Mulder, et al.World Journal of Urology|January 9, 2013
Sequential therapy with targeted agents in metastatic renal cell carcinoma: beyond second-line and overcoming drug resistanceMuhammad Khattak, James LarkinExpert Opinion on Drug Safety|July 7, 2017
The safety of nivolumab for the treatment of metastatic melanomaAine O'Reilly, James LarkinCancer Management and Research|August 21, 2012
Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanomaRosalie Fisher, James LarkinClinical Genitourinary Cancer|December 5, 2025
Ipilimumab and Nivolumab in Renal Cell Carcinoma: Real-World Experience in Rare Variant Renal Cell Carcinoma, Brain Metastases and Impact of Immune-Related Adverse Events and Steroid UseTobias Peres, James LarkinPageof 74